Literature DB >> 1851830

Interaction of SR 33557 with skeletal muscle calcium channel blocker receptors in the baboon: characterization of its binding sites.

J Sol-Rolland1, M Joseph, M Rinaldi-Carmona.   

Abstract

A procedure for the isolation of primate skeletal microsomal membranes was initiated. Membranes exhibited specific enzymatic markers such as 5'-nucleotidase, Ca++,Mg(++)-adenosine triphosphatase and an ATP-dependent calcium uptake. Baboon skeletal microsomes bound specifically with high-affinity potent Ca++ channel blockers such as dihydropyridine, phenylalkylamine and benzothiazepine derivatives. Scatchard analysis of equilibrium binding assays with [3H](+)-PN 200-110, [3H](-)-desmethoxyverapamil [( 3H](-)-D888) and [3H]-d-cis-dilitiazem were consistent with a single class of binding sites for the three radioligands. The pharmacological profile of SR 33557, an original compound with calcium antagonist properties, was investigated using radioligand binding studies. SR 33557 totally inhibited the specific binding of the three main classes of Ca++ channel effectors and interacted allosterically with them. In addition, SR 33557 bound with high affinity to a homogeneous population of binding sites in baboon skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851830

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  2 in total

1.  Inhibitory action of SR33557 on L-type calcium current in single ventricular myocytes of rat.

Authors:  K Yasui; P Palade
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

2.  Identification of a novel calcium antagonist binding site in rat brain by SR 33557.

Authors:  B A Kenny; S Fraser; M Spedding
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.